5Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal celldeath. Mol Neurobiol, 2001, 24(1 -3): 107-129.
6Park KW, Nozell SE, Benveniste EN. Protective role of STAT3 in nmda and glutamate-induced neuronal death: negative regulatory effect of SOCS3. PloS one, 2012, 7 ( 11 ) : e50874.
7Nguyen D, Alavi MV, Kim KY, et al. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis, 2011, 2 (12): e240.
8Zhang C, Du F, Shi M, et al. Ginsenoside Rd Protects Neurons Against Glutamate-Induced Excitotoxicity by Inhibiting CaInflux. Cell Mol Neurobiol, 2012, 32( 1 ) : 121 - 128.
9Shen Y, Liu XL, Yang XL. N-methyl-D-aspartate receptors in the retina. Mol Neurobiol, 2006, 34(3) : 163 - 179.
10Izumi Y, Hammerman SB, Kirby CO, et al. Involvement of glutamate in ischemic neurodegeneration in isolated retina. Visual Neurosci, 2003, 20(2) : 97 - 107.
2ELDER J A. Ocular effects of radiofrequency energy [J].Bioelectromagnetics, 2003, 6 (2) : 148-161.
3GARRIGA P, MANYOSA J. The eye photoreceptor pro- tein rhodopsin. Structural implications for retinal disease [J]. FEBS Lett, 2002, 528 (1-3) : 17-22.
4FLIESLER S J,ANDERSON R E. Chemistry and metabolism of lipids in the vertebrate retina [J]. Prog Lipid Res, 1983, 22 (2) : 79-131.
5CHAHORY S,PADRON L,COURTOIS Y,et al. The LEI/L-DNase II pathway is activated in light-induced reti- nal degeneration in rats [J]. Neurosci Lett, 2004,367 (2) : 205-209.
6KISELEV A, SOCOLICH M, VINOS J, et al. A molecular pathway for light-dependent photoreceptor apoptosis in Drosophila[J]. Neuron, 2000, 28 (1) 139-152.
7BONFOCO E, KRALNC D, ANKARCRONA M,et al. Apoptosis and necrosis:two distinct events induced,respec- tively,by mild and intense insults with N-methyl-D-as- paxtate or nitric oxide/supperoxide in cortical cell cultures [J]. PNAS, 1995, 92 (16) 7162-7166.
1Gautret P, Gray GC, Charrel RN, et al. Emerging viral re spiratory tract infections environmental risk factors and trans mission [J]. Lancet Infect Dis,2014,14(11):1113- 1122.
2Zumla A, Memish ZA, Maeurer M,et al. Emerging novel and antimicrobiai-resistant respiratory tract infections: new drug development and therapeutic options[J]. I.ancet Infect Dis, 2014,14(11) :1136- 1149.
3Gao HN,Lu HZ,Cao B,et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection[J]. N Engl J Med, 2013, 368(24) :2277- 2285.
4Yu H, Cowling BJ, Feng L, et al. Human infection with avi an influenza A H7N9 virus: an assessment of clinical severity [-J]. Lancet,2013,382 (9887) :138- 145.
5Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1 [J]. J Infect Dis,2012,206(9) : 1359- 1366.
6Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a random ised controlled trial. Neuraminidase Inhibitor Flu TreatmentInvestigator Group [J]. Lancet, 2000, 355 (9218) : 1845 - 1850.
7Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients ad- mitted to hospital with influenza A H1Nlpdm09 virus infec- tion: a meta-analysis of individual participant data[J]. Lancet Respir Med,2014,2(5) :395 - 404.
8Hu Y, Lu S, Song Z, et al. Association between adverse clini- cal outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of an- tiviral resistance[J]. Lancet,2013,381 (9885) :2273 - 2279.
9Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospital- ized with influenza A and B infections[J]. Clin Infect Dis, 2013, 57(11) :1511 - 1519.
10Hayden FG. Newer influenza antivirals, biotherapeutics and combinations [J]. Influenza Other Respir Viruses, 2013, 7 (Suppl 1):63 75.
